Liver cirrhosis breakthrough. This study Aug 22, 2023 · Scientists found that a drug, Pegozafermin, which mimics the body’s hormone, improved liver fibrosis and inflammation in NASH patients. I am not sure how this will help people with genetic conditions like PBC, hemochromatosis (sp) etc. Dec 16, 2024 · Scientists have found two types of MASLD—one targeting the liver and another impacting various organs—which could enhance diagnosis and treatment approaches for this widespread disease. Breakthrough Device Designation for a diagnostic indication is a recognition by FDA that earlier assessment using a blood test—the ELF Test—may address an unmet medical need. By addressing a population with no approved therapies, it could redefine treatment standards. 1,2 Therefore, COVID-19 vaccination for patients with cirrhosis is widely recommended. Aug 14, 2024 · The most common symptoms of PBC are pruritus and fatigue, which can be debilitating for some people. By the time liver tumors were large, often inoperable and deeply embedded in sensitive vascular landscapes, options dwindled to palliative care. The research reveals that D-lactate, generated by intestinal microbes, prompts the liver to manufacture excessive amounts of sugar and fat. Data from the MEV01 trial presented at the 2024 American Association for the Study of Liver Diseases (AASLD) Liver Meeting Jul 2, 2024 · A study on mice offers promising results for millions suffering from non-alcoholic liver disease. 9% with placebo after 48 weeks of treatment [response difference Oct 8, 2024 · The U. Sep 8, 2025 · Stem Cells: A Stunning Breakthrough in Liver Disease Therapy Stem cells hold immense promise for regenerative medicine, and recent advancements are offering new hope for individuals battling debilitating liver diseases. Researchers hope that this could lead to more surgical options for patients diagnosed with advanced liver tumors and liver failure. 5% of adults with fibrosis stages F2 and F3 (moderate to advanced scarring) achieved an improvement in fibrosis without worsening of metabolic dysfunction-associated steatohepatitis (MASH), versus 25. The findings, published in the prestigious New England Feb 16, 2025 · Research achieves gene-editing breakthrough that could improve treatment for liver disease, other disorders Date: February 16, 2025 Source: Rice University Summary: Researchers developed a new Jan 9, 2025 · Hepatocellular carcinoma represents approximately 90 percent of primary liver cancers. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on Delve into liver cirrhosis, its challenges, and the potential of stem cell therapy. Utilizing these Aug 21, 2025 · Clinical trials demonstrated that semaglutide led to MASH resolution in 63% of patients without worsening liver scarring, marking a breakthrough for fatty liver disease treatment. Jan 9, 2024 · Using this new technology has allowed us to study human liver scarring in high definition for the first time, and we hope that this state-of-the-art approach will allow us to accelerate the discovery of much-needed new treatments for patients with liver disease. The liver, despite being one of the body's most robust organs, remains susceptible to damage from stress and aging, which can lead to disease, significant scarring, and even organ failure. This chronic liver condition can lead to serious health conditions including severe liver fibrosis or cirrhosis and liver cancer, posing a significant public health […] Aug 25, 2025 · After diagnosis with liver disease, patient Rosa Tellez-Moore opts to participate in clinical trials, which change the trajectory of her treatment. This novel oral therapy may revolutionise how advanced cirrhosis is Mar 14, 2024 · A New Dawn in Liver Health: Fatty Liver Foundation Applauds Breakthrough FDA Approval of REZDIFFRA™ (resmetirom) for MASH Treatment BOISE, ID – MARCH 14, 2024 – The Fatty Liver Foundation (FLF) heralds a significant milestone in the field of liver health with the U. Researchers at Karolinska Aug 15, 2025 · MASH is a progressive disease that can lead to cirrhosis (severe liver scarring), hepatic decompensation (worsening of liver function), liver cancer, liver transplantation, or death. It disproportionately affects individuals with obesity, type 2 diabetes, or metabolic syndrome—populations already familiar with semaglutide as a treatment for diabetes (Ozempic) and weight loss (Wegovy Apr 29, 2014 · Has everyone seen the article yet on the breakthrough with treating cirrhosis. The U. We isolated 278,457 total CLD patients: 43,079 (15%) vaccinated and Jan 4, 2023 · Using the latest technologies—including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells—researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD). The COVID-19 pandemic has had a profound impact on patients with liver disease. However, engineered macrophage cell therapy aims to repair and regenerate damaged liver tissue, potentially offering a more effective treatment option. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on survodutide’s groundbreaking results from Phase II study 1 Boehringer launches two Phase III studies Jun 10, 2024 · A healthy liver has a fat content of just 5% or less by weight, but in MASH fat can rise to unhealthy levels that put people at risk for cirrhosis, liver cancer or even the need for a liver transplant. Using nanocarriers loaded with the VEGF Dec 23, 2024 · The Company received US FDA approval for the alfa pump System for the treatment of recurrent or refractory ascites due to liver cirrhosis in December 2024, following the grant of FDA Breakthrough Nov 19, 2020 · The Digestive Health Institute at UCI Health has developed a groundbreaking, noninvasive method to accurately measure blood pressure in the liver, which could accurately assess liver the organ's health and potentially help millions of people avert severe liver disease. However, patients with advanced liver disease like cirrhosis often have immune dysfunction and may respond poorly to vaccines. all CLD patients with or without cirrhosis who had SARS‐CoV‐2 testing in the N3C Data Enclave as of January 15, 2022. May 14, 2025 · GSK secures phase III-ready liver disease breakthrough with potential best-in-class monthly dosing. Credit: Shutterstock A new investigational treatment targets the root cause of a life-threatening liver condition Feb 13, 2025 · The Rice lab of bioengineer Gang Bao and collaborators at Baylor College of Medicine have developed a new gene-editing strategy that dramatically boosts the effectiveness of gene therapies in the liver, a breakthrough that could lead to new treatments for about 700 genetic disorders in this vital organ as well as in other organs and tissues. Two types of fatty liver disease discovered, enhancing diagnosis and treatment. Liver cirrhosis, stem cell therapy, liver disease, liver treatment, cirrhosis breakthrough, stem cell research, liver health, chronic liver disease, stem cell benefits, liver regeneration, cirrhosis management, cell-based Aug 24, 2008 · Liver fibrosis, triggered by chronic liver damage produced by hepatitis infection, alcohol abuse, or fatty liver disease, can lead to cirrhosis, a major health problem worldwide. 1 NEW Breakthrough for Fatty Liver Recovery in Just 3 Days! | Barbara O'Neill Discover how to reverse fatty liver naturally in just 2 weeks with Barbara O'Neill's powerful herbal remedies and Mar 5, 2025 · Contact: Eileen Teves, 210-450-7239, tevese@uthscsa. S. In a nationwide, multi-center clinical trial, scientists May 1, 2025 · These diseases begin with fat building up in liver cells, but can worsen to involve inflammation, cell damage, and eventually cirrhosis, a potentially fatal liver condition. Mar 6, 2023 · Our findings showing that rifaximin-α seems to reduce progression of liver fibrosis represent a major clinical breakthrough in the management of alcohol-related liver disease. There is a long way to go but we may be seeing the first real evidence of direct treatment for advanced fibrotic disease. Gideon Hirschfield, is Director of the Autoimmune Liver Disease Program at UHN’s Francis Family Liver Clinic and Toronto Centre for Liver Disease and holds the Lily and Terry Horner Chair in Autoimmune Liver Disease Research. The EASL– Lancet commission calls for actions towards early and reversible stages of liver disease. Jul 5, 2025 · In a breakthrough for liver health, scientists at the University of Sunderland have developed two experimental drugs—DR-3 and FDR2—that may not just slow liver disease, but actually reverse fibrosis. A spokesperson from the British Liver Trust Mar 14, 2024 · “Treating NASH is so important because it is the fastest-growing cause of cirrhosis, liver cancer, and liver transplant. Chronic liver diseases, including cirrhosis and liver failure, remain formidable challenges due to their complex progression and limited therapeutic options. 1 May 26, 2025 · For decades, a diagnosis of advanced liver cancer felt like a sentence more than a diagnosis—a terminal verdict delivered with few avenues for reprieve. Their research has led to Boehringer Ingelheim today announced breakthrough results from a survodutide Phase II trial sub-analysis that demonstrate up to 64. The introduction of genetic engineering has popularized the use of porcine models, and we hope Sep 14, 2022 · The paper starts by highlighting the importance of COVID - 19 vaccines. A groundbreaking cell therapy involving macrophage immune cells The U. 8 billion in 2019-20 alone (Deloitte Access Economics Report: The Social and Economic Cost of Primary Liver Cancer). FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on survodutide’s groundbreaking results from Phase II study1 Boehringer launches two Phase III studies of survodutide, LIVERAGE in adults with MASH and moderate or advanced fibrosis, and LIVERAGE May 10, 2025 · Rezdiffra's Breakthrough in Compensated Cirrhosis: A New Era for Liver Disease Treatment?The recent presentation of late-breaking data from Madrigal Pharmaceuticals’ Phase 3 MAESTRO-NAFLD-1 trial has sent ripples through the hepatology space. It plays a pivotal role in metabolism, regulation of biochemicals, and filtering of blood. Apr 24, 2025 · EvoLiver's FDA Breakthrough Device designation could swing liver cancer surveillance tests from ultrasound to blood-based. The treatment May 3, 2021 · Cirrhosis and other chronic liver diseases remain a global health concern, with close to 2 million deaths reported annually, these account for approximately 3. Mar 3, 2025 · San Antonio has one of the highest rates of metabolic dysfunction-associated steatotic liver disease (MASLD) in the United States, largely driven by high rates of obesity and diabetes in the region. provided two EASL position papers1,2 to promote the optimal response to COVID-19 for patients with liver disease. Experts hope the medication, designated a “breakthrough therapy,” proves to be a sign of more treatments to come. Dec 7, 2023 · PBC is a rare, progressive, autoimmune cholestatic liver disease 1 in which bile ducts in the liver are gradually destroyed. By targeting the HDAC6 enzyme, these compounds significantly reduced liver scarring in lab models without causing toxicity, offering a promising path toward curing chronic liver damage. Keeping Breakthrough data at EASL Congress 2025 marks a new chapter in liver disease care From reversing cirrhosis and diagnosing silent liver disease, to delivering potential cures and new therapies for chronic liver diseases, EASL Congress 2025 showcases major advances. A new type of cell therapy to treat patients with liver scarring, or cirrhosis, shows promise of being the first medical treatment for this common and lethal condition. Apr 11, 2024 · Liver diseases affect up to 1 in 3 Australian adults. This cancer is most commonly found in people living with chronic viral hepatitis, heavy alcohol use, or metabolic dysfunction-associated steatotic liver disease. Jun 24, 2023 · Researchers with UC San Diego School of Medicine identified a potential new drug that improved liver fibrosis in patients with NASH by 27%. Liver cirrhosis, stem cell therapy, liver disease, liver treatment, cirrhosis breakthrough, stem cell research, liver health, chronic liver disease, stem cell benefits, liver regeneration, cirrhosis management, cell-based While invasive liver biopsy was required to detect cirrhosis, the development of magnetic resonance elastography (MRE) has revolutionized our ability to detect liver fibrosis through non-invasive means that involve measurement of liver stiffness. Oct 8, 2024 · The U. This creates a vicious cycle, leading to severe health consequences. Liver cirrhosis due to fatty liver is the most common indication for liver transplantation in the United States in people over 65 years of age and in women. Dec 23, 2024 · The Company received US FDA approval for the alfa pump System for the treatment of recurrent or refractory ascites due to liver cirrhosis in December 2024, following the grant of FDA Breakthrough Device Designation in 2019. Feb 21, 2024 · Better Therapeutics wins breakthrough status for health app to treat liver disease The FDA awarded the designation after seeing evidence the digital cognitive behavioral therapy may help reduce liver fat. This remarks the achievement of a target long-pursued by the scientific Oct 1, 2025 · A breakthrough blood test called CORE can predict the risk of severe liver disease such as cirrhosis or liver cancer up to 10 years before symptoms begin. Advanced non-alcoholic fatty liver disease can lead to cirrhosis, the only cure of which is a liver transplant. The scar tissue blocks the flow of blood through Nov 21, 2023 · Researchers have devised a novel approach that harnesses the patient's own cells to aid in the treatment of liver cirrhosis. The CORE calculator requires a simple Mar 30, 2025 · Researchers discovered a mechanism after acute liver damage occurs—and it could lead to treatments for those with severe liver problems. Apr 9, 2025 · In a remarkable display of modern regenerative medicine, a 61-year-old woman from Mumbai has successfully reversed her liver cirrhosis through advanced stem cell therapy at the Viecell Institute Definition and Importance Cirrhosis refers to the progressive scarring of liver tissue, resulting from chronic liver injury. Mar 10, 2025 · Treatment with efruxifermin led to reversals of liver scarring in adults with MASH, a severe form of fatty liver disease, in a Phase 2 trial. by Apr 9, 2025 · In a remarkable display of modern regenerative medicine, a 61-year-old woman from Mumbai has successfully reversed her liver cirrhosis through advanced stem cell therapy at the Viecell Institute of Regenerative Medicine in Surat. edu Content provided by Claire Kowalick SAN ANTONIO, March 5, 2025 – A study published in Nature Aging has revealed a promising new drug candidate that may help combat metabolic dysfunction-associated steatotic liver disease (MASLD), a chronic liver condition that disproportionately affects communities in San Antonio due to high rates of Apr 15, 2024 · Introduction Cirrhosis is associated with a substantial, and increasing, health and socioeconomic burden worldwide. As a vital organ, the liver is responsible for numerous essential functions, including detoxifying harmful substances, synthesizing crucial proteins, and aiding digestion. Progression of PBC is associated with an increased risk of liver-related mortality. Sep 11, 2025 · A harmful molecule produced by gut bacteria could be fuelling Britain's liver disease epidemic, scientists have warned. Feb 10, 2025 · The risk of developing liver cancer is increased in people who have cirrhosis, a disease in which healthy liver tissue is replaced by scar tissue. May 1, 2025 · In a discovery that could reshape the future of liver disease treatment, researchers have revealed groundbreaking results from the global ESSENCE Phase III clinical trial, showing that semaglutide —a drug originally developed for diabetes and weight loss—can not only halt but even reverse a dangerous liver condition known as MASH. Delve into liver cirrhosis, its challenges, and the potential of stem cell therapy. We used Poisson regression to estimate incidence rates of breakthrough infections and Cox survival analyses to associate vaccination status with all‐cause mortality at 30 days among infected CLD patients. All Oct 14, 2024 · The U. — A new drug has been shown to increase healing and regeneration of the liver after major surgery, according to a study published in the scientific journal Cell. Approximately 1 in 4 people worldwide have non-alcoholic fatty liver disease, however there are currently no medications to specifically treat this condition. Sep 13, 2025 · Scientists at UC San Diego have tested a new drug that directly targets fat production in the liver, offering a potential breakthrough for people with advanced fatty liver disease. The leading causes of cirrhosis are steatotic liver diseases (including alcohol-related liver disease and metabolic dysfunction-associated steatohepatitis (MASH, formerly nonalcoholic steatohepatitis (NASH)) and chronic viral Jul 28, 2025 · Liver disease remains a global health concern, affecting millions and potentially leading to severe complications if not properly treated. On March 14, 2024, after more than 25 years of intense research and a long series of failures, the Food and Drug Administration approved resmetirom as first drug for the treatment of non-alcoholic steatohepatitis (NASH) with fibrosis (now Metabolic-Associated Steatotic Liver Disease - MASLD). Aug 21, 2024 · HCV infection is the underlying cause for chronic Hepatitis C (CHC), liver cirrhosis, and liver cancer or hepatocellular carcinoma (HCC). The Food and Drug Administration (FDA) approved resmetirom (Rezdiffra™) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. Traditional therapies often focus on managing symptoms and slowing disease progression. Using nanocarriers loaded with the VEGF-C protein, researchers were able to restore lymphatic drainage, reduce fluid buildup, and lower portal pressure in animal models. $2B total deal value includes milestone payments. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on survodutide’s groundbreaking results from Phase II study 1 Boehringer launches two Phase III studies A team of Indian scientists has developed a groundbreaking treatment for liver cirrhosis by targeting damaged lymphatic vessels in the liver and intestine. The only independent factor predicting infection in cirrhosis was low albumin level. This breakthrough suggests niacin could be repurposed as a Apr 24, 2025 · The FDA has granted breakthrough device designation to the EvoLiver test, developed by Mursla Bio, for surveillance of hepatocellular carcinoma (HCC) in patients with high-risk cirrhosis. Researchers Oct 8, 2024 · The U. For years, treatment options for severe liver conditions have been limited, often culminating in the need for a liver transplant. Unchecked, nonalcoholic fatty liver disease can progress to NASH, a leading cause of liver transplantation. Jan 10, 2025 · The UK is facing a liver disease crisis, with the number of deaths doubling in the last 20 years. and Marjot et al. In nonalcoholic steatohepatitis, fat deposits in the liver and persistent chronic inflammation results in the destruction of liver cells, eventually leading to liver cirrhosis 4. With limited treatment options available, the promising results from the Phase 2 MATCH trial are an encouraging breakthrough for patients with liver cirrhosis. Although there are several drugs in development for the treatment of fatty liver, none of them have yet been approved for use. Introduction Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non‐alcoholic fatty liver disease (NAFLD), is a significant global health problem characterized by macrovesicular steatosis involving at least 5% of hepatocytes without secondary causes such as alcohol or drug abuse [1]. Mesenchymal stem cell (MSC) therapy has emerged as a game-changing approach, leveraging its Jan 29, 2025 · Akero just announced the results of its phase 2b Symmetry clinical trial of its FGF21 analog for F4 cirrhosis due to NASH/MASH and those results are just super. 5% of annual worldwide deaths. Cirrhosis is associated with higher COVID-19-related morbidity and mortality. About Gilead Sciences in Liver Disease For decades, Gilead has pioneered the way forward to improve the lives of people living with liver disease around the world. Scientists have uncovered how ammonia wreaks havoc on liver cells by damaging mitochondria Apr 30, 2025 · Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and Mar 7, 2025 · A new study reveals that ammonia, a toxin accumulating in liver disease patients, directly harms liver cells by damaging mitochondria. These results represent a significant milestone in the development of treatments for NASH/MASH with compensated A study led by the University of Edinburgh has looked at a new type of cell therapy for people with cirrhosis. Feb 26, 2025 · Is There a Breakthrough in Cirrhosis Treatment? A New Study Suggests So A groundbreaking study is challenging conventional wisdom on cirrhosis treatment, offering a potential lifeline for millions suffering from this devastating liver disease, particularly prevalent in India and other tropical countries. Food and Drug Administration (FDA) has granted breakthrough therapy status to survodutide, an experimental injectable therapy by Boehringer Ingelheim for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease. Read the blog to discover. Results for Rezdiffra (resmetirom), a thyroid hormone receptor beta (THR-β) agonist, demonstrated statistically significant improvements in liver Mar 14, 2024 · ROCHESTER, Minn. Jan 7, 2021 · A breakthrough treatment for cirrhosis of the liver could be available within five years, saving thousands of lives a year, after a major clinical trial showed promising results. 1,2,3 Common symptoms of PBC include fatigue and pruritus (itch), which Sep 13, 2024 · Learn about the potential benefits, treatment methods, and self-healing properties of stem cell therapy for liver cirrhosis. Discover if this pioneering treatment could be the solution you've been searching for. May 1, 2025 · These diseases begin with fat building up in liver cells, but can worsen to involve inflammation, cell damage, and eventually cirrhosis, a potentially fatal liver condition. "This research is significant because this is the first drug of its kind to show an Oct 8, 2024 · The U. Obesity is a prime factor driving fatty liver disease. Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a condition that affects billions worldwide. Currently, there are no FDA-approved treatments for NASH, a common and often silent liver disease. ” Jun 27, 2024 · The introduction of RTX001 may revolutionize how decompensated liver cirrhosis is treated. I plan on talking to my hepatologist when I see her again. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on survodutide’s groundbreaking results from Phase II study1 Boehringer launches two Phase III studies of survodutide, LIVERAGE in adults with MASH and moderate or advanced fibrosis, and LIVERAGE Sep 12, 2025 · Researchers identified microRNA-93 as a genetic driver of fatty liver disease and showed that vitamin B3 can effectively suppress it. Their research has led to the development of a promising new drug that could change the treatment landscape for this prevalent disease. MASLD encompasses a spectrum of liver conditions, including cirrhosis After HBV infection, activated immune cells attack the infected hepatocytes, resulting in extensive liver destruction. Previous studies on veteran populations showed some results regarding vaccination in patients with chronic liver diseases (CLD) but knowledge gaps remain for non - veteran populations. Sep 1, 2024 · In this paper, we review the latest research progress on pigs as models for human liver diseases, including cystic fibrosis liver disease (CFLD), acute liver failure (ALF), MASLD, and liver tumors, as well as liver regeneration and xenotransplantation, for which they offer significant advantages. Nov 19, 2024 · MASH is a severe progression of non-alcoholic fatty liver disease (NAFLD), characterized by liver inflammation and fibrosis that can lead to cirrhosis, liver failure, or even liver cancer. The pr … Apr 19, 2024 · A drug that targets liver scarring from fatty liver disease gained Food and Drug Administration accelerated approval in March, marking the first-ever drug specifically for the disease to get the FDA’s nod. They found that the treatment could reduce the risk of serious liver complications, and could in future help to prevent hospital admissions and deaths. 1,2 Cornberg et al. At the moment over 4,000 people die every year in the UK from liver cirrhosis. See trial results. The liver, often termed the body's detox center, showcases how internal functions can go awry. Feb 22, 2024 · The lead author, Dr. A team of Indian scientists has developed a groundbreaking treatment for liver cirrhosis by targeting damaged lymphatic vessels in the liver and intestine. Once grappling with the progression of Non-Alcoholic Fatty Liver Disease (NAFLD) to Non-Alcoholic Steatohepatitis (NASH), her condition had reached a critical stage Aug 2, 2025 · A team of Indian scientists has developed a groundbreaking treatment for liver cirrhosis by targeting damaged lymphatic vessels in the liver and intestine. Using nanocarriers loaded with the VEGF Sep 1, 2024 · March 14, 2024 signs a historical turning point in the treatment of metabolic-associated steatotic liver disease (MASLD). In cirrhosis, the reduced response is associated with older age, stage of liver disease and systemic inflammation, and breakthrough infection with low albumin level. Apr 29, 2024 · This is an important breakthrough. Mar 26, 2024 · A significant breakthrough in treatment prospects. They think they might me able to even reverse cirrhosis. Conclusions: LT patients present the lowest response to the SARS-CoV-2 vaccine. May 10, 2025 · Conclusion: A Game-Changer for Liver Disease? Resmetirom’s data in compensated MASH cirrhosis represent a breakthrough. A new £30 million study is aiming to speed up the development of new treatments for advanced liver cirrhosis. . Scientists have developed a calculator, the Cirrhosis Outcome Risk Estimator (CORE), to predict an individual's risk of severe liver disease within 10 years. With researchers anticipating 27 million cases of NASH in the U. The research was led by investigators at the Icahn School of Medicine at Mount Sinai. In 2019, over 2,90,000 people died of HCV-related diseases Apr 29, 2014 · Has everyone seen the article yet on the breakthrough with treating cirrhosis. I am sure this will help people with hepc, alcohol induced cirrhosis and fatty liver disease. With 42% of NASH patients progressing to cirrhosis, Rezdiffra’s potential to slow or reverse fibrosis offers a lifeline. Food and Drug Administration’s (FDA) approval of REZDIFFRA™ (resmetirom), developed by Madrigal Pharmaceuticals, for Aug 12, 2020 · Chronic liver disease is challenging to diagnose, but the microbiome inside a person’s gut may be an unexpected solution, says Salk research. When the liver is damaged—whether by chronic alcohol consumption, viral hepatitis 1. This marks the first such liver cancer test to receive this status in over 5 years. If untreated, liver disease can progress to liver cancer which is the fastest-growing cause of cancer death in Australia, costing $4. Apr 23, 2025 · The FDA has given the EvoLiver test breakthrough device designation for the surveillance of hepatocellular carcinoma (HCC) in patients with high-risk cirrhosis, according to a news release from the drug’s developer, Mursla Bio. Feb 10, 2025 · In a significant advancement for the treatment of patients with cirrhosis, researchers have demonstrated the potential for effective liver tumor removal using a minimally invasive surgical approach Feb 6, 2025 · Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a condition that affects billions worldwide. 2 The damage to bile ducts can inhibit the liver’s ability to rid the body of toxins, and can lead to scarring of liver tissue, known as cirrhosis. ddv wxxpa5n gx u81c fqn5bk l3exqsm crqu vpyzgn l4eto if